Cargando…
Reply to: “Comment on “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?””
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Association for the Study of the Liver. Published by Elsevier B.V.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272678/ https://www.ncbi.nlm.nih.gov/pubmed/34146650 http://dx.doi.org/10.1016/j.jhep.2021.06.008 |
| _version_ | 1783721261325615104 |
|---|---|
| author | Bril, Fernando Fettig, David M. |
| author_facet | Bril, Fernando Fettig, David M. |
| author_sort | Bril, Fernando |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8272678 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Association for the Study of the Liver. Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82726782021-07-20 Reply to: “Comment on “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?”” Bril, Fernando Fettig, David M. J Hepatol Letter to the Editor European Association for the Study of the Liver. Published by Elsevier B.V. 2021-10 2021-06-17 /pmc/articles/PMC8272678/ /pubmed/34146650 http://dx.doi.org/10.1016/j.jhep.2021.06.008 Text en © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Bril, Fernando Fettig, David M. Reply to: “Comment on “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?”” |
| title | Reply to: “Comment on “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?”” |
| title_full | Reply to: “Comment on “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?”” |
| title_fullStr | Reply to: “Comment on “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?”” |
| title_full_unstemmed | Reply to: “Comment on “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?”” |
| title_short | Reply to: “Comment on “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?”” |
| title_sort | reply to: “comment on “autoimmune hepatitis developing after coronavirus disease 2019 (covid-19) vaccine: causality or casualty?”” |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272678/ https://www.ncbi.nlm.nih.gov/pubmed/34146650 http://dx.doi.org/10.1016/j.jhep.2021.06.008 |
| work_keys_str_mv | AT brilfernando replytocommentonautoimmunehepatitisdevelopingaftercoronavirusdisease2019covid19vaccinecausalityorcasualty AT fettigdavidm replytocommentonautoimmunehepatitisdevelopingaftercoronavirusdisease2019covid19vaccinecausalityorcasualty |